Compare Incyte Corporation (INCY) vs CarMax, Inc (KMX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs CarMax, Inc — how do they compare? Incyte Corporation trades at $112.79 (market cap $22.85B), while CarMax, Inc trades at $52.61 (market cap $7.64B). The key difference: Incyte Corporation is far larger — about 3× CarMax, Inc's market cap, and CarMax, Inc is more actively traded (3,610,116 versus 1,927,029). Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and CarMax, Inc for 49 Days on average.
| INCY | KMX | |
|---|---|---|
Market Cap | $22.85B | $7.64B |
Volume | 1,927,029 | 3,610,116 |
Sector | Health | Consumer Cyclical |
52-Week High | $129.93 | $64.22 |
52-Week Low | $83.80 | $30.88 |
Typical Hold Time | 33 Days | 49 Days |
Enterprise Value | $18.35B | $25.34B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $112.75, down 0.61% on the day, with a bearish technical signal despite strong fundamentals. The company reported robust 2025 results with $5.14B revenue and $1.29B net income, showing significant margin expansion. Recent FDA approval for Atebrioz and pipeline progress support growth prospects beyond JAKAFI's 2029 exclusivity loss. Analyst consensus is bullish with a $132.43 price target, though technical indicators show selling pressure near key resistance.
Outlook remains positive driven by pipeline diversification and operational leverage, but near-term technical weakness and reliance on JAKAFI transition pose risks. The stock offers value with a 14.36 P/E ratio and strong profitability metrics, though investors should monitor execution on the $4B non-JAKAFI sales target and quarterly earnings consistency.
CarMax (KMX) trades at $53.79, up 0.96% with a bearish technical outlook despite recent earnings beats. The company reported strong Q2 2027 results with EPS of $1.16 beating expectations by 58%, driven by 19.5% revenue growth to $7.9 billion. Valuation metrics show a P/E of 25.37 and P/S of 0.28, while profitability remains challenged with a 1.06% net margin. The stock faces resistance near $54-55 with support at $52-53 levels.
KMX shows early turnaround progress with improved sales volume and earnings, but faces margin pressure and high debt levels. The consensus price target of $58.89 suggests 9.5% upside potential, though analyst sentiment is cautious with 62% hold ratings. Key risks include competitive pricing pressure and macroeconomic sensitivity to used car demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About CarMax, Inc
CarMax sells, finances, and services used and new cars through a chain of over 230 used retail stores. It was formed in 1993 as a unit of Circuit City and spun off into an independent company in late 2002. Used-vehicle sales typically account for about 83% of revenue and wholesale about 13%, with the remaining portion composed of extended service plans and repair. In fiscal 2022, the company retailed and wholesaled 924,338 and 706,212 used vehicles, respectively. CarMax is the largest used-vehicle retailer in the U.S. but still estimates that it has only about 4% U.S. market share of vehicles 0-10 years old in 2021. It seeks over 5% share by the end of calendar 2025 and revenue between $33 billion to $45 billion by fiscal 2026. CarMax is based in Richmond, Virginia.
Read more on KMX →
